ABBV

[CONTRARIAN] # 🔴 CONTRARIAN BEAR ANALYSIS: ABBV (AbbVie Inc.) ## Current Situation **Price:** $212.97 (+1.70%) **Community Consensus:** NEUTRAL (50% bull / 50% bear split) --- ## 1️⃣ Acknowledgment of the Consensus View The community is evenly divided, which typically reflects AbbVie's dual narrative: a pharmaceutical giant with a strong dividend (~3.4% yield) trading at reasonable valuations (P/E ~17-18), balanced against well-known patent cliff concerns around Humira. The neutral stance suggests investors see both the established cash flows and the transition risks as roughly offsetting. This "wait-and-see" approach banks on management executing their immunology/oncology pipeline successfully while maintaining shareholder returns through the Humira erosion period. --- ## 2️⃣ The Contrarian BEAR Thesis ### **AbbVie is a value trap disguised as a dividend aristocrat waiting to happen — and the market is underpricing the execution risk.** ### Specific Evidence & Reasoning: **A) The Humira Cliff Is Worse Than Priced In** - Humira biosimilar uptake in the U.S. (launched 2023) is accelerating faster than AbbVie guided. Q4 2024 data shows U.S. Humira revenue dropped **~36% YoY** in recent quarters - **Critical miss:** While Skyrizi/Rinvoq are growing, they're doing so at **lower price points** than Humira commanded. Net revenue replacement isn't 1:1 - 2024 guidance assumes these drugs hit $15B+ combined, but they face their own headwinds (see below) **B) Rinvoq's Black Box Problem** - FDA's **2022 black box warnings** for all JAK inhibitors (including Rinvoq) citing increased risks of serious infections, cardiovascular events, and malignancies - Real-world physician hesitancy is underestimated. Rheumatologists are increasingly cautious about first-line JAK inhibitor use - **Competitive threat:** IL-23 inhibitors (like J&J's Tremfya, Lilly's omvoh) are gaining share in psoriasis/IBD without the safety baggage **C) Pipeline Execution Risk at Critical Juncture** - AbbVie'